Some examples include: Abaloparatide (Tymlos) and Teriparatide (Forteo) for osteoporosis Degarelix (Firmagon) for advanced prostate cancer Dulaglutide (Trulicity), exenatide (Byetta), liraglutide (Victoza), lixisenatide (Adlyxin), tirzepatide (Mounjaro), and semaglutide (Ozempic) for Type 2 diabetes Semaglutide (Wegovy) and tirzepatide (Zepbound) for weight loss Linaclotide (Linzess) for irritable bowel syndrome with constipation Ziconotide (Prialt) for severe chronic pain These medications are carefully designed to target specific receptors and biological pathways, allowing for precise treatment of certain conditions
Response: We note that for CY 2026, OPPS payment rates are based on available CY 2024 claims data
In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), 0.2% of ZEPBOUND-treated patients had acute pancreatitis confirmed by adjudication (0.14 patients per 100 years of exposure) versus 0.2% of placebo-treated patients (0.15 patients per 100 years of exposure)
AOD-9604, sometimes called the fat-burning peptide, showed limited promise in animal studies but has failed to demonstrate consistent results in people, leading the FDA to explicitly state it is not an approved treatment (FDA on unapproved drugs)